QUREHealthcare · BiotechnologyThe 13 Wall Street analysts covering uniQure NV hold a median 12-month price target of $64 — +158.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 38 of 100 as at 31 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores uniQure NV on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (88): The business earns solid, repeatable profits on what it owns.
Volatility (10): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on QURE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +158.0% from it.
Of the 20 most recent actions, 4 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 15 Oct 2026 | UBS | Assumes | Buy | $27 → $48 |
| 5 Oct 2026 | Barclays | Downgrade | Equal-Weight | $60 → $28 |
| 5 Oct 2026 | Barclays | Downgrade | Equal-Weight | — |
| 2 Oct 2026 | RBC Capital | Maintains | Outperform | — |
| 2 Oct 2026 | RBC Capital | Maintains | Outperform | $65 → $48 |
| 30 Sept 2026 | Goldman Sachs | Maintains | Neutral | $46 → $31 |
| 30 Sept 2026 | Goldman Sachs | Maintains | Neutral | — |
| 2 Sept 2026 | William Blair | Reinstates | Outperform | — |
| 30 July 2026 | Barclays | Maintains | Overweight | — |
| 30 July 2026 | Barclays | Maintains | Overweight | $65 → $60 |
| 30 July 2026 | Wells Fargo | Maintains | Overweight | — |
| 30 July 2026 | Wells Fargo | Maintains | Overweight | $60 → $75 |
| 30 July 2026 | Wolfe Research | Upgrade | Outperform | — |
| 30 July 2026 | Wolfe Research | Upgrade | Outperform | $65 |
| 29 June 2026 | HC Wainwright & Co. | Maintains | Buy | $50 → $80 |
| 29 June 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 25 June 2026 | Mizuho | Maintains | Outperform | $35 → $68 |
| 25 June 2026 | Mizuho | Maintains | Outperform | — |
| 18 June 2026 | Barclays | Upgrade | Overweight | — |
| 18 June 2026 | Goldman Sachs | Maintains | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
QURE appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, uniQure NV returned −63.4% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 92% of US stocks
Cheaper than 4% of US stocks
Cheaper than 18% of US stocks
Cheaper than 84% of US stocks
Higher than 55% of US stocks
Higher than 50% of US stocks
Higher than 98% of US stocks
Higher than 6% of US stocks
Higher than 99% of US stocks
Higher than 9% of US stocks
Higher than 22% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
uniQure NV has a market value of $1.7B and an enterprise value of $1.5B.
Revenue in the twelve months to 30 June 2026: $18.7M. The latest quarter grew 11.0% year on year.
Net income over the same four quarters: −$252.2M, a −1350.7% net margin.
Free cash flow in the twelve months to 30 June 2026: −$161.5M.
Trailing P/E: −7.2×; forward P/E: −8.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
uniQure NV employs 221 people — $84K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own uniQure NV — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research highlighted ILMN, QURE and TXG in a roundup of genomics stocks, citing the expanding markets for precision medicine and gene editing.
Why it matters — The item places QURE among companies featured in a broader discussion of genomics and synthetic biology, without providing company-specific developments.
uniQure announced that it will host an earnings call on Wednesday, November 4, 2026, at 8:30 a.m. ET, to discuss its third-quarter 2026 financial results.
Why it matters — The announcement gives QURE watchers the date and time of the company’s upcoming financial-results call.
The Seeking Alpha item highlights uniQure’s Huntington’s gene therapy BLA under FDA accelerated review, with a decision expected around November 1. It cites three-year data showing 75% slowing of the composite endpoint and 60% slowing of Total Functional Capacity, and gives the stock a Speculative Buy rating with a $47 price target.
Why it matters — The FDA review timeline and reported clinical results are key developments for QURE watchers.
Cedar Grove Capital said it closed its long position in uniQure during the quarter, as reported in its Q3 2026 portfolio update.
Why it matters — The update indicates Cedar Grove Capital no longer held a long position in QURE at quarter-end.
Kirby McInerney LLP said it is investigating possible federal securities law violations or other unlawful business practices by uniQure and/or its senior management. The notice references a 37.3% share drop and the company’s September 29, 2026 release of 48-month data from ongoing Phase I/II AMT-130 studies.
Why it matters — QURE investors may follow the investigation and the cited AMT-130 data release as developments involving the company.
The 13 Wall Street analysts covering uniQure NV have a median 12-month price target of $64, with estimates ranging from $28 to $91. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 13 analysts covering uniQure NV, 11 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks uniQure NV 38 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, uniQure NV ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (88 of 100).
No one can know that. What the data says: the median 12-month target from 13 analysts implies +158.0% from the last close, and Ticker Nerd's factor model ranks uniQure NV 38 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering uniQure NV publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for QURE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $28 to $91 over the next 12 months.
uniQure NV returned -63.4% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
uniQure N.V. is a biopharmaceutical company focused on gene therapy for patients with severe genetic and other serious diseases.
The most recent item we track (Zacks Investment Research, 30 Oct 2026): "3 Promising Genomics Stocks to Add to Your Portfolio Now". Zacks Investment Research highlighted ILMN, QURE and TXG in a roundup of genomics stocks, citing the expanding markets for precision medicine and gene editing.
uniQure N.V. is a biopharmaceutical company focused on gene therapy for patients with severe genetic and other serious diseases. Its current portfolio includes HEMGENIX for hemophilia B and a pipeline of investigational therapies aimed at disorders such as Huntington’s disease, epilepsy, ALS, and Fabry disease. The company uses an adeno-associated virus (AAV) platform to develop one-time treatments designed to address the underlying cause of disease, with activities spanning research, development, manufacturing, and commercialization. Headquartered in Amsterdam, the Netherlands, uniQure serves the rare-disease and specialty therapeutic markets through both proprietary programs and selected partnerships.
CEO Mr. Matthew Craig Kapusta CPA · 221 employees · Netherlands · https://www.uniqure.com
